Epstein-Barr virus A Review

Authors

  • Rahul Agarwal
  • Monika Malhotra
  • Rajeev Kr. Sharma

DOI:

https://doi.org/10.37591/rrjoi.v1i1-3.1155

Abstract

The unravelling of the molecular pathogenesis of malignancy that had its beginnings in the last third of the twentieth century was, in many ways, sparked by the discovery of virus-associated tumors and oncogenic viruses. Epstein Barr virus (EBV) and other viruses that soon followed were not only exciting stories in themselves but provided models with starting points and outcomes, which, since they were specific, could be dissected and generalized. In these annals, EBV qualifies as a human tumor virus, the first identified virus. According to the latest survey of the literature, it has all the features of DNA tumor viruses including consistency of association with given tumors at the epidemiological and molecular level and oncogenic properties in cell culture and animal models. The diversity of tumors caused by or associated with EBV infection, which are both lymphoid and epithelial in origin, is certainly the greatest for any tumor virus and complicates questions of causality. EBV-associated tumors include lymphomas, carcinomas, and even rare myosarcomas. However, this seemingly paradoxical spectrum can be rationalized by the pathobiologic features of EBV infection. Even mild or non-life-threatening infection with EBV can, occasionally, be associated with the development of serious complications from the infection and if a particular blood cell involved in the immune response, almost all organs systems can ultimately be affected by EBV infection.

Keywords: Epstein-Barr virus, Hodgkin's lymphoma, gastrin carcinoma, nasopharyngeal carcinoma, Burkitt's lymphoma

Downloads

Published

2019-04-02

Issue

Vol. 1 No. 1-3 (2011)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.